Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed Combined With EGFR-TKI for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
NCT05805631Phase 2Recruiting
- Sponsor
- Taipei Veterans General Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM), sponsored by Taipei Veterans General Hospital. Primary endpoint: Disease Control Rate. Started Aug 2024; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT05805631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805631.